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Objectives: Studies have demonstrated the importance of the environment both 
on the development of asthma and on exacerbation of asthma symptoms in those 
who have been diagnosed with the disease. The goal of this project was to pro-
vide in-home asthma services that covered both self-management education and 
home environmental interventions for children diagnosed with asthma living in 
Section 8 Multi-family Housing. MethOds: This HUD-funded project consisted 
of 3-4 home visits by a public health nurse over a one year period—an in-home 
baseline visit; a visit to deliver allergen-reducing products if needed; and 6 and 
12-month follow-ups by phone or in-home visit. Data was collected on asthma 
status (health-related quality of life and asthma control), health service utilization 
(hospitalizations, ED and office visits) and school and/or work absences due to 
asthma. Data analysis was completed using SAS v9.3. Results: 219 children from 
161 low income families were enrolled from five participating local public health 
agencies in a large metropolitan area. The low cost interventions provided, resulted 
in significant increases in the proportion of enrollees experiencing minimal to no 
daytime and nighttime symptom burden and functional limitations at the 12-month 
follow-up (p< 0.05). Overall health care service use declined. There was a significant 
reduction in school days missed (p< 0.05), the equivalent of 5 school days per child 
per year. The average cost per family of interventions, was $424 (e.g. mattress and 
pillow encasements, HEPA vacuum cleaners, air purifiers). Program administra-
tive costs per family were $585 (e.g. enrollment costs, travel time, visit time and 
documentation). cOnclusiOns: This study provided additional support for the 
usefulness and success of providing home interventions for low income children 
who have been diagnosed with asthma. Low cost, targeted interventions led to 
improvements in HRQOL, decreased health service utilization, increased school 
attendance and a positive return on investment.
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Objectives: The aim of our study was to analyze the generic competition of medica-
ments containing the active substance montelukast sodium and to examine the 
cost-containment methods of the Hungarian National Health Insurance Fund 
Administration. MethOds: Data derived from the nationwide pharmaceutical 
database of Hungarian National Health Insurance Fund Administration (2007-2013). 
We analyzed the turnover and price of the medicaments containing the active sub-
stance montelukast sodium. Accordingly our indicators were: consumer price, social 
insurance subsidy, patients’ co-payment and defined daily dose (DOT). Results: 
The price of Singulair 10 mg tablets was 32 USD in October 2011, when the generics 
appeared, and it was reduced to 10 USD by the end of 2013. The generics started 
with a price 40% lower (for example Montelukast Teva 10 mg tablets: 19 USD, Eonic 
10 mg tablets: 17 USD, Montelukast Sandoz 10 mg tablets: 19 USD), their price was 
diminished below 7.4 by the end of 2013 (for example: Montelukast Teva 10 mg tablets: 
5.2 USD, Eonic 10 mg tablets: 5.8 USD, Montelukast Sandoz 10 mg tablets: 5.5 USD). 
The DOT increased gradually: In 2007 it was 1.7 million days, in 2010 6.3 million days 
and in 2013 it increased over 10 million days. The amount of the health insurance 
subsidy was 9.2 million USD in 2010. It reached its peak in 2011 (10.5 million USD) , in 
2012 it was reduced to 7 million USD, in 2013 to 4.1 million USD, in all it is a setback 
of 61%. cOnclusiOns: Following the introduction of generic drugs, the price of the 
medicaments containing montelukast sodium was significantly reduced. The annual 
health insurance subsidy was significantly reduced as well, while the DOT increased. 
The patients’ access to drugs containing montelukast sodium increased significantly.
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Objectives: Chronic obstructive pulmonary disease (COPD) is one of the most 
common lung diseases. COPD prevalence among US adults was estimated to be 
15 million or 6.3 percent of the total population in 2011. Nonadherence to COPD 
maintenance medications has been reported to be associated with more hospitaliza-
tions, higher mortality and lower quality of life. This study examined COPD mainte-
nance medication adherence among Medicare beneficiaries with COPD. MethOds: 
An observational, retrospective cohort study was conducted using 2007 and 2008 
Medicare Current Beneficiary Survey (MCBS) data. Sample inclusion criteria were 
being diagnosed with COPD and having at least two Medicare Part D claims. 
Medication adherence was measured by calculating proportion of days covered 
(PDC). PDC was calculated as the number of days with COPD maintenance medica-
tions available divided by total number of days in a six-month period following 
index dates, which were defined as the date of first COPD maintenance medica-
tion fill in 2007. A dichotomous variable was used to determine adherence status. 
Individuals with PDCs of 0.80 or greater were considered adherent and individuals 
with PDCs less than 0.80 were considered nonadherent. Logistic regressions were 
used to examine associations between demographic variables and medication 
adherence. Results: A total of 292 beneficiaries fulfilled sample selection criteria 
and were included in the analysis. The mean age was 72 years, 54 percent were ≤ 
75 years old and 11 percent were 85 years or older. The sample was predominantly 
female (60%) and white (85%). The mean±standard deviation PDC was 0.69±0.24. 
More than half (59%) of the Medicare beneficiaries had PDC of less than 0.80 and 
were classified as nonadherent to their COPD maintenance medications. No sig-
label prospective study was conducted among 208 COPD patients who were 
admitted in a tertiary care teaching hospital in south India after obtaining the 
ethical clearance. Demographics, medication adherence and quality of life 
of the patients were measured using Morisky scale (Adherence) & St. George 
Respiratory Questionnaire (HRQoL). Statistical analyses were performed using 
SPSS®version 20. Results: Mean age of the study population (n= 208) was 
58.42±9.72.(Males = 93.5%) . After the drug treatment, males showed statistically 
significant (p < 0.05) improvement in pulmonary function, medication adher-
ence and HRQoL. Patients with COPD duration of < 5 years showed a signifi-
cant improvement in pulmonary function and HRQoL scores. Literate patients 
had a significantly higher improvement in Medication Adherence and HRQoL 
than illiterate patients. cOnclusiOns: The results of the study suggest that 
demographic factors were independently associated with outcomes in COPD 
patients.
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Objectives: Tobacco smoking is the leading cause of preventable morbidity 
and mortality in the United States, and smoking cessation has multiple health 
benefits. The purpose of this study was to assess cigarette smokers’ preference 
towards characteristics of tobacco cessation medications using a Willingness-to-Pay 
approach. MethOds: Data from the 2008 Healthstyles Survey, a mail-based prob-
ability sample of 5,399 adult aged ≥ 18 years, were used to assess three primary out-
comes among current cigarette smokers (n= 914): 1) interest in quitting; 2) interest 
in using cessation medications; and 3) willingness to pay for six types of cessation 
medications. Point estimates and 95% confidence intervals were calculated overall 
and by sociodemographic and smoking behavior characteristics. Multivariate Probit 
regression analysis was used to evaluate smokers’ willingness to pay in relation 
to perceived importance of three cessation medication characteristics: conveni-
ence of use, over-the-counter availability, and efficiency to help quit. All models 
controlled for sociodemographic characteristics, smoking behavior characteristics, 
and U.S. region fixed effects. Results: Approximately 68.4% of current cigarette 
smokers were interested in quitting. Among these individuals, 45.6% indicated that 
they were interested in using cessation medications, and of these, 47.3% indicated 
that they were willing to pay $150 or more out-of-pocket for these medications. 
Convenience of use and the effectiveness of these medications to help quit were 
positively associated with current smokers’ willingness to pay for $300 or more 
(p≤ 5%); however, no association was observed for over-the-counter availability. 
Self-reported exposure to telephone quitline advertisements was also positively 
associated with the willingness-to-pay. cOnclusiOns: Approximately 68% of cur-
rent smokers are interested in quitting and about half of those smokers interested 
in quitting are also interested in using cessation medications. Convenience of use 
and the medication’s effectiveness are important to smokers with quit intentions. 
Understanding these preferences may help inform efforts to increase access and 
utilization of cessation medications.
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Objectives: Allergic asthma (AA) patients comprise over 93% of severe/difficult 
to treat cases in the US and patients face a lifelong treatment course. A dearth of 
real world information exists on the use of effective and approved treatments, 
particularly among adolescents. This study examined medication treatments for 
AA patients and incorporated treatment intensity (HighTx), consistent with NHLBI 
treatment guidance (steps 5-6), as a severity proxy. MethOds: This retrospec-
tive, observational study used MarketScan claims to identify newly diagnosed 
AA patients (10/2009 – 9/2012). Two cohorts were established: adolescents (12-17); 
adults (18-64). Index was the date of first AA diagnosis. Continuous enrollment 
was required for 12 months before and after index. Demographics and comorbidi-
ties were measured at baseline. Asthma medication use was observed in the 12 
months after index. HighTx was characterized for patients with high dose inhaled 
corticosteroid/long-acting beta agonist (ICS/LABA) combination treatment and 
having > 30 days supply in any continuous treatment period in 12 months after 
index. Results: Gender distribution differed across age cohorts (adolescents: 
> 50% female; adults: > 65% male). Acute illness drove comorbidity burden: more 
adolescents experienced acute respiratory infections (37.9% vs. 24.5% adult); more 
adults reflected acute sinusitis (20.6% vs. 25.2% adult). Treatment patterns (full 
sample): more adolescents received short-acting beta agonist (35.5% vs. 30.2% 
adults); fewer received ICS/LABA (22.6% vs. 34.5% adults) and monoclonal anti-
bodies (0.3% vs. 1.1% adults). Treatment pattern (HighTx): more patients received 
ICS/LABA (adolescents 98.9%; adults 99.3%); days on therapy did not exceed 160 
(ICS/LABA) for either HighTx age cohort. Twice as many HighTx adults received 
monoclonal antibodies as adolescents (2.5% vs. 5.1% adults). cOnclusiOns: In 
light of similar disease burden, AA diagnosis, and availability of effective treat-
ments, fewer AA adolescents received targeted therapies than adults. This dispar-
ity highlights the opportunity to incorporate targeted therapies as a treatment 
option, particularly for adolescent AA patients.
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will exceed the cumulative cessation cost in the 11th year and it will be 2.5 times 
in the 20th year; the cumulative medical cost plus productivity saving will exceed 
the cumulative cessation cost in the 7th year and it will be 3.4 times in the 20th 
year. cOnclusiOns: Considering the attractive ROI results, it’s recommended that 
SC medicines should be covered in the SC intervention.
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Objectives: To assess epinephrine auto-injector (EAI) availability and use for ana-
phylactic events in US schools during the 2013-2014 school year. MethOds: This 
exploratory, cross-sectional, web-based survey analyzed anaphylactic events in eli-
gible schools participating in the Mylan-sponsored EpiPen4Schools® program, an 
ongoing initiative providing free EAIs and training to schools nationwide. Results: 
Survey participants consisted of 6019 of the > 40,000 schools in the EpiPen4Schools 
program. A total of 919 anaphylactic events were reported in 11% of schools (607/5683). 
Importantly, 22% of anaphylactic events (n= 187) occurred in individuals with no 
known allergies; most events (89%, 757/852) occurred in students. Of the 851 events 
with treatment information, 75% of individuals (n= 636) were administered epineph-
rine via an EAI, 49% (n= 310) of whom used the schools’ stock EAI provided through 
the EpiPen4Schools program (despite known prior allergies in 69% of anaphylactic 
cases). Of note was the disparity between the number of qualifying schools in the 
EpiPen4Schools program, nationwide, with Illinois having the highest (n= 2282) and 
District of Columbia the lowest (n= 4) number of participating schools. cOnclusiOns: 
One in 10 schools participating in the survey reported ≥ 1 anaphylactic event during 
the 2013-2014 school year. Of those individuals treated with EAIs, nearly half used 
their school’s stock EAI, provided through the EpiPen4Schools program, suggesting 
the value of stocking EAIs for student/staff safety and potential cost savings. Studies 
on the cost of inpatient care for anaphylaxis indicate approximately $4700 per event. 
Furthermore, data suggest significantly higher treatment costs and poorer outcomes 
when treatment with an EAI is delayed. The prevalence of anaphylaxis continues to 
increase, as do the costs associated with receiving treatment and delaying or failing 
to receive treatment; removing barriers to access and increasing availability of treat-
ment is an important public health goal.
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Objectives: The study aimed to evaluate the level of disease state knowledge among 
tuberculosis patients. MethOds: A questionnaire based cross-sectional study was car-
ried out among patients with TB in Fatima Jinnah chest hospital Quetta. Data was col-
lected by a pre-tested structured questionnaire that contain twenty two (22) regarding 
information related to TB (including etiology, symptoms, transmission, diagnosis and 
treatment). The descriptive statistics was used to present the data. Inferential statistics 
was used to the evaluation relationship among study variables. All analyses were per-
formed using SPSS 20.0. Results: Majority (60.0%) of the study patients were female 
and belong to age group of 22 to 31 years (24.28%). Majority (41.4%) of the respondents 
were illiterate and had received religious education(31.4%). The mean knowledge score 
was 11.23 ± 3.6 which is categorized as poor knowledge and posters/broachers and 
other printed material was reported as major source of information. No demographic 
characteristic was influencing the mean knowledge scores. cOnclusiOns: The study 
concluded that the TB patients had poor disease state knowledge. Efforts should be 
made educate the patients regardless to the demographic characteristics, so that better 
disease control and further spread of infection would be prevented.
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Objectives: The presence of adverse events (AEs) associated with topical rosacea 
agents may lead to a lack of treatment adherence. Previous studies have reported 
low adherence rates among treated rosacea patients. This study describes the rate 
of treatment changes due to AEs and associated healthcare costs among rosacea 
patients receiving a topical therapy. MethOds: Patients diagnosed with rosacea 
(ICD-9-CM: 695.3) who are newly initiating treatment with topical metronidazole, 
azelaic acid, sodium sulfacetamide/sulfur, benzoyl peroxide between 1/2009 and 
10/2013 were identified from MarketScan databases. Patients were required to 
be ≥ 30 years old, continuously eligible with medical and pharmacy benefits ≥ 12 
months pre- and ≥ 3 months post-treatment and without evidence of oral antibiotic 
or rosacea conjunctivitis during the study period. An AE was defined as a treatment 
switch within 2 weeks or medical claim with an AE diagnosis code. Persistence was 
defined as continuous refill of the index drug/formulation within 1.5 times the days’ 
supply of the prior prescription. Rate of AEs, treatment patterns, and healthcare 
costs were evaluated in the post-index period. Results: This analysis included 
49,351 patients. The mean age was 54 years and 25.5% were male. Metronidazole 
(72.7%) was the most common treatment and the predominant formulation was gel 
nificant differences were found in adherence across age groups (p= 0.34), genders 
(p= 0.43), or races (p= 0.62). cOnclusiOns: Adherence to COPD maintenance medi-
cations was low among Medicare beneficiaries with COPD.
PRS49
tHe eaRly ImPaCt of CloSIng tHe CoveRage gaP on annual dRug 
exPendItuReS, out-of-PoCket SPendIng, dRug utIlIzatIon, and aCCeSS 
to PReSCRIPtIon among SenIoRS WItH CHRonIC CondItIonS
Bonakdar A.
Virginia Commonwealth University, Richmond, VA, USA
Objectives: To measure the extent to which closing the coverage gap will affect drug 
utilization, access, and OOP spending among seniors with chronic diseases, includ-
ing respiratory diseases (asthma or COPD), hypertension, hyperlipidemia, psychosis, 
depression, and diabetes. MethOds: A difference-in-difference-in-difference (DDD) 
analysis from 2008 to 2012 was used. Results: The Medical Expenditure Panel Survey 
data files from 2008 to 2012 imply that closing the coverage gap had no significant 
impact on the disparities in annual drug expenditures, OOP spending, and total num-
ber of prescriptions between minorities and whites. However, it significantly increased 
the disparity in access to prescriptions between minorities and whites by 3.8 percent. 
When teasing out the effect by race, the results show that closing the coverage gap 
had no significant impact on the disparities in OOP spending and total number of pre-
scriptions between African-Americans and whites, while it significantly increased the 
disparity in access to prescriptions for by 7.3 percent, and significantly decreased the 
disparity in annual drug expenditures by $1,162. Regarding Hispanics, it significantly 
increased the disparities in OOP spending and total number of prescription drugs by 
$325 and 8 prescriptions, respectively. However, it had no significant impact on the 
disparities in annual drug expenditures and access to prescriptions. cOnclusiOns: 
The findings of this study demonstrate that the benefits of closing the coverage gap 
are disproportionately distributed among different racial groups. Closing the coverage 
gap decreased disparities in annual drug expenditures, OOP spending, and access to 
prescription drugs for African-American compared to white, while It increased dis-
parities in annual drug expenditures, OOP spending, and total number of prescription 
for Hispanics compared to whites.
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Objectives: Decisions regarding formulary generosity of exchange-based plans have 
undoubtedly affected uptake of specific therapies at a time of guaranteed-issue cover-
age and out-of-pocket maximums. This study examined formulary decisions made by 
managed care organizations for their exchange-based plans, and assessed the impact 
of these decisions on brand prescribing for asthma, bipolar disorder, and multiple 
sclerosis, to discern differences between indications. MethOds: Surveys of 120 MCO 
pharmacy and medical directors, and 270 pulmonologists, psychiatrists, neurologists, 
and primary care physicians were conducted in 2014 and 2015 to determine formulary 
coverage on exchange-based plans, and the impact of this coverage on brand prescrib-
ing to patients covered by such plans. Results: Some 41% of surveyed MCOs reported 
the formularies of their exchange-based plan and largest commercial plan to be dis-
tinct; the exchange-based plans of 52% of these respondents covered fewer brands 
overall. Furthermore, increased tier 3+ (non-preferred) coverage and/or exclusion of 
some brands in/from their exchange-based plans versus their largest commercial plans 
were noted by an average of 8%, 10%, and 0% of MCOs for asthma, bipolar disorder, 
and multiple sclerosis drugs, respectively. In response, surveyed physicians reported 
decreased prescribing of specific drugs, particularly those competing versus generics, 
that were subject to less favorable/complete lack in exchange-based coverage versus 
traditional commercial coverage. The greatest impact of less favorable exchange-based 
plan coverage on uptake was on bipolar disorder, where, for example Seroquel XR 
was prescribed to 8% of exchange-based plan patients versus 5% of commercial plan 
patients. cOnclusiOns: Less-generous reimbursement on exchange-based plans is 
evident, demonstrating desires by MCOs to limit costs on these plans. Consequently, 
there is increased prescribing of generics and preferred brands when available over 
higher-cost agents. Therapy areas with a number of cheaper options will be most 
affected, while specialty therapy areas will remain largely immune to this trend.
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Objectives: Knowing the return-on-investment of smoking cessation (SC) is critical 
for policy makers to understand its economic benefit and implement effective SC 
intervention. The study sought to assess the return-on-investment (ROI) of smoking 
cessation in Guangdong, China and inform its economic benefit to policy mak-
ers. MethOds: A decision tree model about ROI of SC benefit comparison was 
developed and adapted, which compared the costs, benefits and outcomes of 2 
SC benefit scenarios over 20-year time frame. The main difference between the 2 
scenarios was whether SC medicines were covered or not. Key inputs were obtained 
from available public sources, including smoking population, potential medical 
costs and savings along with productivity improvement, participants’ expected 
quit rates and relapses, etc. Results: If SC medicines are covered, the number 
of attempts and successes will increase 11 million and 1.3 million respectively 
in 20 years in Guangdong; the annual medical cost saving will exceed the annual 
cessation cost in the 6th year and it will be 7.7 times in the 20th year; the annual 
medial cost plus productivity saving will exceed the annual cessation cost in the 
4th year and it will be 9.5 times in the 20th year; the cumulative medical cost saving 
